

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC2/18 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 27.11.2018

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test		N	Result	N _{rel}
Sample	Group			
(601) A1 expression HER-2/neu				
Slide	(802) Dako HercepTest	1	Negative (1)	2,3 %
		>>>	8 Weak positivity	18 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	8 Weak positivity	18 %
		>	3 Strong positivity	6,8 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	18 Weak positivity	41 %
		>	4 Strong positivity	9,1 %
	(999) another manufacturer	>>>	2 Weak positivity	4,5 %
Total per sample: n = 44		Success: 98 %		
Total success: 98 %				
(602) A2 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	9 Negative (0)	20 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Negative (0)	25 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22 Negative (0)	50 %
	(999) another manufacturer	>>>	2 Negative (0)	4,5 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(603) A3 expression HER-2/neu				
Slide	(802) Dako HercepTest	4	Negative (1)	9,1 %
		>>>	5 Weak positivity	11 %
	(803) Dako c-erbB-2 Onkoprotein	1	Negative (1)	2,3 %
		>>>	10 Weak positivity	23 %
	(804) Ventana PATHWAY anti-HER-2/neu	3	Negative (1)	6,8 %
		>>>	19 Weak positivity	43 %
	(999) another manufacturer	1	Negative (1)	2,3 %
		>>>	1 Weak positivity	2,3 %
Total per sample: n = 44		Success: 80 %		
Total success: 80 %				
(606) B1 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	9 Negative (0)	20 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Negative (0)	25 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22 Negative (0)	50 %
	(999) another manufacturer	>>>	2 Negative (0)	4,5 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(607) B2 expression HER-2/neu				
Slide	(802) Dako HercepTest	1	Negative (1)	2,3 %
		>>>	8 Weak positivity	18 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	9 Weak positivity	20 %
		>	2 Strong positivity	4,5 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	20 Weak positivity	45 %
		>	2 Strong positivity	4,5 %
	(999) another manufacturer	>>>	2 Weak positivity	4,5 %
Total per sample: n = 44		Success: 98 %		
Total success: 98 %				
(608) B3 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	9 Strong positivity	20 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Strong positivity	25 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22 Strong positivity	50 %
	(999) another manufacturer	>>>	2 Strong positivity	4,5 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(611) C1 expression HER-2/neu				
Slide	(802) Dako HercepTest	1	Negative (1)	2,3 %
		>>>	8 Weak positivity	18 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Weak positivity	25 %
	(804) Ventana PATHWAY anti-HER-2/neu	1	Negative (1)	2,3 %
		>>>	19 Weak positivity	43 %
		>	2 Strong positivity	4,5 %
	(999) another manufacturer	1	Negative (1)	2,3 %
		>>>	1 Weak positivity	2,3 %
Total per sample: n = 44		Success: 93 %		
Total success: 93 %				

Test		N	Result	N _{rel}
Sample	Group			
(612) C2 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	9 Strong positivity	20 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Strong positivity	25 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22 Strong positivity	50 %
	(999) another manufacturer	>>>	2 Strong positivity	4,5 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(613) C3 expression HER-2/neu				
Slide	(802) Dako HercepTest		1 Negative (1)	2,3 %
		>>>	8 Weak positivity	18 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	9 Weak positivity	20 %
		>	2 Strong positivity	4,5 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	21 Weak positivity	48 %
		>	1 Strong positivity	2,3 %
	(999) another manufacturer		1 Negative (1)	2,3 %
		>>>	1 Weak positivity	2,3 %
Total per sample: n = 44		Success: 95 %		
Total success: 95 %				
(616) D1 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	9 Negative (0)	20 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Negative (0)	25 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	21 Negative (0)	48 %
		>	1 Negative (1)	2,3 %
	(999) another manufacturer	>>>	2 Negative (0)	4,5 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(617) D2 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	9 Negative (0)	20 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Negative (0)	25 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22 Negative (0)	50 %
	(999) another manufacturer	>>>	2 Negative (0)	4,5 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(618) D3 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	9 Negative (0)	20 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	10 Negative (0)	23 %
		>	1 Negative (1)	2,3 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	20 Negative (0)	45 %
		>	2 Negative (1)	4,5 %
	(999) another manufacturer	>>>	2 Negative (0)	4,5 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(621) E1 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	9 Strong positivity	20 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Strong positivity	25 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22 Strong positivity	50 %
	(999) another manufacturer	>	1 Weak positivity	2,3 %
		>>>	1 Strong positivity	2,3 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(622) E2 expression HER-2/neu				
Slide	(802) Dako HercepTest		7 Negative (1)	16 %
		>>>	2 Weak positivity	4,5 %
	(803) Dako c-erbB-2 Onkoprotein		2 Negative (1)	4,5 %
		>>>	9 Weak positivity	20 %
	(804) Ventana PATHWAY anti-HER-2/neu		4 Negative (1)	9,1 %
		>>>	18 Weak positivity	41 %
	(999) another manufacturer		1 Negative (1)	2,3 %
		>>>	1 Weak positivity	2,3 %
Total per sample: n = 44		Success: 68 %		
Total success: 68 %				
(623) E3 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	9 Negative (0)	20 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Negative (0)	25 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22 Negative (0)	50 %
	(999) another manufacturer	>>>	2 Negative (0)	4,5 %
Total per sample: n = 44		Success: 100 %		

Test

Sample	Group	N	Result	N _{rel}
Total success: 100 %				
(651) A1 sample staining				
Slide	(0) not specified	>	2 9 points	4,5 %
		>>>	42 15 points	95 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(652) A2 sample staining				
Slide	(0) not specified	>>>	44 15 points	100 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(653) A3 sample staining				
Slide	(0) not specified		1 0 points	2,3 %
		>	7 9 points	16 %
		>	1 11 points	2,3 %
		>>>	35 15 points	80 %
Total per sample: n = 44		Success: 98 %		
Total success: 98 %				
(656) B1 sample staining				
Slide	(0) not specified	>>>	44 15 points	100 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(657) B2 sample staining				
Slide	(0) not specified	>	2 9 points	4,5 %
		>>>	42 15 points	95 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(658) B3 sample staining				
Slide	(0) not specified	>	2 12 points	4,5 %
		>>>	1 13 points	2,3 %
		>>>	41 15 points	93 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(661) C1 sample staining				
Slide	(0) not specified	>	1 12 points	2,3 %
		>>>	43 15 points	98 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(662) C2 sample staining				
Slide	(0) not specified	>	1 12 points	2,3 %
		>>>	2 13 points	4,5 %
		>>>	41 15 points	93 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(663) C3 sample staining				
Slide	(0) not specified	>	2 9 points	4,5 %
		>>>	42 15 points	95 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(666) D1 sample staining				
Slide	(0) not specified	>>>	1 14 points	2,3 %
		>>>	43 15 points	98 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(667) D2 sample staining				
Slide	(0) not specified	>>>	1 14 points	2,3 %
		>>>	43 15 points	98 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(668) D3 sample staining				
Slide	(0) not specified	>>>	1 13 points	2,3 %
		>>>	43 15 points	98 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				
(671) E1 sample staining				
Slide	(0) not specified		1 5 points	2,3 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC2/18 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 27.11.2018

Test			N	Result	N _{rel}
Sample	Group				
Slide	(0) not specified	>	3	12 points	6,8 %
		>>>	1	13 points	2,3 %
		>>>	39	15 points	89 %
----- Total per sample: n = 44		----- Success: 98 %	-----		
Total success: 98 %					
(672) E2 sample staining					
Slide	(0) not specified		1	0 points	2,4 %
			1	5 points	2,4 %
		>	1	9 points	2,4 %
		>>>	1	13 points	2,4 %
		>>>	37	15 points	90 %
----- Total per sample: n = 41		----- Success: 95 %	-----		
Total success: 95 %					
(673) E3 sample staining					
Slide	(0) not specified	>>>	44	15 points	100 %
----- Total per sample: n = 44		----- Success: 100 %	-----		
Total success: 100 %					
(681) IQC					
Slide	(0) not specified		2	0 points (unacceptable result)	4,5 %
			7	3 points (unacceptable result)	16 %
			1	4 points (unacceptable result)	2,3 %
		>	1	5 points (acceptable result)	2,3 %
		>	10	6 points (acceptable result)	23 %
		>	1	7 points (acceptable result)	2,3 %
		>>>	1	8 points (excellent result)	2,3 %
		>>>	21	9 points (excellent result)	48 %
----- Total per sample: n = 44		----- Success: 77 %	-----		
Total success: 77 %					

st_kl

End of report

Printed: 14.12.2018